We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

LIEN:NASDAQChicago Atlantic BDC, Inc. Analysis

Data as of 2026-04-15 - not real-time

$9.44

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Chicago Atlantic BDC (LIEN) is trading at $9.44, well below its 20‑day ($9.54), 50‑day ($9.87) and 200‑day ($10.38) moving averages, indicating a short‑term bearish bias. The stock sits just above the calculated support of $9.16 and faces resistance near $10.20, while volume has been trending downwards. Valuation metrics are compelling – a trailing P/E of 6.4 versus an industry average of 17.5, a price‑to‑book of 0.71 and a DCF‑derived fair value of $28.75 suggest significant upside potential, estimated at roughly 16.5% by the model. However, the company carries a very high debt‑to‑equity ratio of 8.24, negative operating cash flow and a dividend payout ratio of 93%, raising concerns about the sustainability of its 14.4% yield.
The latest earnings release highlights robust credit performance: $31.7 million of new senior‑secured, floating‑rate loans originated, $11 million of repayments collected, and zero loans in non‑accrual status (industry average 3.3%). While revenue grew 12.5% year‑over‑year and margins remain strong (>55% operating, >60% net), the firm’s exposure to the cannabis sector adds a layer of regulatory risk. The market sentiment is extremely bullish (Fear‑Greed Index 88.6), but the combination of high leverage, dividend sustainability doubts, and sector‑specific regulatory uncertainty tempers enthusiasm.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Price below all key moving averages and decreasing volume
  • High debt load and near‑full dividend payout ratio
  • Proximity to support level with limited upside in the near term

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Significant valuation discount (low P/E, P/B, DCF upside)
  • Strong loan performance with zero non‑accruals and active new originations
  • Target price consensus around $11 indicating ~16% upside

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Regulatory uncertainty in the cannabis financing space
  • High leverage may constrain future cash generation
  • Attractive dividend yield if sustainable, but dependent on cash flow trends

Key Metrics & Analysis

Financial Health

Revenue Growth12.50%
Profit Margin61.29%
P/E Ratio6.4
ROE11.01%
ROA6.20%
Debt/Equity8.24
P/B Ratio0.7
Op. Cash Flow$-20477732
Free Cash Flow$29.7M
Industry P/E17.5

Technical Analysis

TrendBearish
RSI43.1
Support$9.16
Resistance$10.20
MA 20$9.54
MA 50$9.87
MA 200$10.38
MACDBullish
VolumeDecreasing
Fear & Greed Index88.64

Valuation

Fair Value$28.75
Target Price$11.00
Upside/Downside16.53%
GradeUndervalued
TypeBlend
Dividend Yield14.41%

Risk Assessment

Beta0.17
Volatility20.83%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.